Receives approval to manufacture and market generic semaglutide in South Africa - Sun Pharmaceutical Industries Ltd

Code BSE: 524715 NSE:

South Africa is the second market after India where Sun Pharma has received approval for generic semaglutide. This reflects our ability to develop complex generic medicines that meet the stringent quality standards across different markets. We remain committed to improving access to generics and making evidence-based treatment options available to patients and healthcare professionals," said Aalok Shanghvi, Chief Operating Officer, Sun Pharma.